DOI QR코드

DOI QR Code

Clinical Character of Pediatric Head and Neck Rhabdomysarcomas: A 7-Year Retrospective Study

  • Zhang, Wei-Ling (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Zhang, Yi (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Huang, Dong-Sheng (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Guo, Fang (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Han, Tao (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Hong, Liang (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Hu, Hui-Min (Department of Pediatrics, Tong Ren Hospital, Capital Medical University) ;
  • Zhi, Tian (Department of Pediatrics, Tong Ren Hospital, Capital Medical University)
  • Published : 2013.07.30

Abstract

Objective: The rhabdomysarcoma (RMS) is most common soft tissue carcinoma in children, mostly found in the head and neck with high degree of malignancy. The current study aimed to summarize clinical data and evaluate treatment outcome of cases in a single hospital. Methods: Forty-one (24 male, 17 female) children with newly diagnosed RMS in Beijing Tong Ren Hospital were enrolled between November, 2004 and May, 2011. The. Students' t and Chi tests were then performed on retrospectively reviewed clinical data, followed by survival analysis based on the Kaplan Meier method using SPSS 17.0 software. Results: Of all cases, 32 were treated by common chemotherapy, and 3 cases with stage III RMS received high-dose chemotherapy and auto-peripheral blood stem cell transplantation (APBSCT). Side-effects in the former were: I grade for 62.5% (20/32), II grade for 28.1% (9/32), III grade account for 9.275% (3/32). Side-effects of 3 cases with APBSCT: 2 were I grade, 1 was III grade. The median follow-up time of 41 RMS cases was 41 months. Four cases were lost to follow-up, 7 cases recurred, and 5 cases died of cerebral metastasis, witha total survival rate was 86.5% (32/37). CR rate was 67.6% (25/37), PR was 18.9% (7/37). Conclusion: Multidiscipline treatment including chemotherapy, radiotherapy, surgery and auto-PBSCT is highly recommended for pediatric patients with head and neck RMS.

Keywords

Rhabdomysarcoma;children;head and neck;chemotherapy;radiotherapy

Acknowledgement

Supported by : Beijing Science Committee

References

  1. Badr MA, Al-Tonbary YA, Mansour AK, et al (2012). Epidemiological characteristics and survival studies of rhabdomyosarcoma in East egypt: a five-year multicenter study. ISRN Oncol, 2012, 674523.
  2. Barr FG (1999). The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer, 59, s1711-5.
  3. Bearman SI, Appelbaum FR, Buckner CD, et al (1998). Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol, 6, 1562-8.
  4. Breneman J, Meza J, Donaldson SS, et al (2012). Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group D9602 Study. Int J Radiat Oncol Biol Phys, 83, 720-6. https://doi.org/10.1016/j.ijrobp.2011.06.2011
  5. Crist W, Gehan EA, Ragab AH, et al (1995). The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol, 13, 610-30.
  6. Gupta AA, Anderson JR, Pappo AS, et al (2012). Patterns of Chemotherapy-Induced Toxicities in Younger Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer, 15, 1131-7.
  7. Jacobs S, Fox E, Krailo M, et al (2010). Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: report from the chidren's oncology group. Clin Cancer Res, 16, 750-4. https://doi.org/10.1158/1078-0432.CCR-09-1906
  8. Kamimura T, Miyamoto T, Nagafuji K, et al (2011). Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review. Bone Marrow Transplant, 46, 820-6. https://doi.org/10.1038/bmt.2010.207
  9. Koscielniak E, Klingebiel T, Peters C, et al (1997). Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant, 19, 227-31. https://doi.org/10.1038/sj.bmt.1700628
  10. Maurer H, Beltangady M, Gehan E, et al (1998). The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer, 61, 209-20.
  11. Maurer H, Gehan E, Beltangady M, et al. (2003) The Intergroup Rhabdomyosarcoma Study-II. Cancer, 71, 1904-22.
  12. Meza JL, Anderson J, Pappo AS, et al (2006). Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J Clin Oncol, 24, 3844-51. https://doi.org/10.1200/JCO.2005.05.3801
  13. Niwa A, Umeda K, Awaya T, et al (2009). Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation. Pediatr Transplant, 13, 259-62. https://doi.org/10.1111/j.1399-3046.2008.00948.x
  14. Oberlin O, Rey A, Anderson J, et al (2001). Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment-results of an international workshop. J Clin Oncol, 19, 197-204.
  15. O'Brien D, Jacob AG, Qualman SJ, Chandler DS (2012). Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol, 27, 13-22.
  16. Palmieri S, Ferrara F, Leoni F, et al (2007). Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype. Hematol Oncol, 25, 1-5. https://doi.org/10.1002/hon.794
  17. Rechnitzer C, Nielsen OH (1999). Malignant solid tumors in children. Ugeskr Laeger, 161, 2196-201.
  18. Rodeberg D, Arndt C, Breneman J, et al (2005). Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV. J Pediatr Surg, 40, 256-62. https://doi.org/10.1016/j.jpedsurg.2004.09.045
  19. Rodeberg D, Paidas C (2006). Childhood rhabdomyosarcoma. Semin Ped iatr Surg, 15, 57- 62. https://doi.org/10.1053/j.sempedsurg.2005.11.009
  20. Salman M, Tamim H, Medlej F, et al (2012). Rhabdomyosarcoma treatment and outcome at a multidisciplinary pediatric cancer center in Lebanon. Pediatr Hematol Oncol, 29, 322-34. https://doi.org/10.3109/08880018.2012.676721
  21. Trahair T, Andrews L, Cohn RJ (2007) Recognition of Li Fraumeni syndrome at diagnosis of a locally advanced extremity rhabdomyosarcoma. Pediatr Blood Cancer, 48, 345-8. https://doi.org/10.1002/pbc.20795
  22. Turner JH, Richmon JD (2011). Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol Head Neck Surg, 145, 967-73. https://doi.org/10.1177/0194599811417063
  23. Uehara T, Yokota A, Onoda M, Yamamoto K, Terano T (2008). Successful autologous peripheral blood stem cell transplantation for a patient with primary adrenal lymphoma with hemophagocytic syndrome. Clin Lymphoma Myeloma, 8, 184-7. https://doi.org/10.3816/CLM.2008.n.024
  24. Van Gaal JC, Van Der Graaf WT, Rikhof B, et al (2012). The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study. Anticancer Res, 32, 4485-97.
  25. Walterhouse DO, Meza JL, Raney RB, et al (2006). Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol, 24, 18S. https://doi.org/10.1200/JCO.2006.06.1143

Cited by

  1. Embryonal Rhabdomyosarcoma (Botryoid Subtype) Affecting the Buccal Mucosa pp.1936-0568, 2018, https://doi.org/10.1007/s12105-018-0957-8